'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Cipla has increased 9.19% to Rs 6729.69 crore. Sales of Phamaceuticals segment has gone up 8.46% to Rs 6,503.63 crore (accounting for 95.75% of total sales). Sales of New Ventures segment has gone up 35.44% to Rs 288.48 crore (accounting for 4.25% of total sales). Inter-segment sales rose Rs 46.13 crore to Rs 62.42 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 18.91% to Rs 1,518.32 crore. PBIT of Phamaceuticals segment rose 18.87% to Rs 1,572.06 crore (accounting for 103.54% of total PBIT). PBIT of New Ventures segment fell 17.85% to Rs -53.74 crore (accounting for -3.54% of total PBIT).
PBIT margin of Phamaceuticals segment rose from 22.05% to 24.17%. PBIT margin of New Ventures segment ro...
Pleaselogin & subscribe to view the full report.
More Reports
|
|